Abstract
The p53 pathway is inactivated in essentially all human tumors p53 is lost or mutated in over 50% of all human cancers, and the majority of the remaining tumors carry mutations in other components of the pathway. It appears that the main biological function of p53 in vivo is to suppress tumorigenesis, because mice with homozygous deletion of the p53 gene are normal, but develop multiple tumors at an early age. p53 plays a central role in cell cycle control and apoptosis in response to DNA damage and other stresses, and in response to oncogenic activation. Loss of p53 function leads to excessive proliferation due to an inappropriate cell cycle control, or to a reduced apoptosis and an excess survival. This allows propagation of cells with damaged DNA resulting in increased genetic instability and enhanced risk of cancer. The contribution of each of the p53 functions, or the lack thereof, to tumor initiation and progression has been studied in vivo, in genetically modified mice. Mice with deletions of one or both p53 alleles have been crossed with mice expressing dominant oncogenes, or lacking other tumor suppressor genes, in order to analyse the genetic interaction between different tumorigenic pathways in vivo. These studies have defined how oncogenic mutations can cooperate in tumorigenesis in tissue and the tumor-specific ways.
Keywords: tumor suppression, oncogene, tumorigenesis
Current Genomics
Title: Studies of p53 Tumor Suppression Activity in Mouse Models
Volume: 3 Issue: 4
Author(s): Dionisio Martin-Zanca
Affiliation:
Keywords: tumor suppression, oncogene, tumorigenesis
Abstract: The p53 pathway is inactivated in essentially all human tumors p53 is lost or mutated in over 50% of all human cancers, and the majority of the remaining tumors carry mutations in other components of the pathway. It appears that the main biological function of p53 in vivo is to suppress tumorigenesis, because mice with homozygous deletion of the p53 gene are normal, but develop multiple tumors at an early age. p53 plays a central role in cell cycle control and apoptosis in response to DNA damage and other stresses, and in response to oncogenic activation. Loss of p53 function leads to excessive proliferation due to an inappropriate cell cycle control, or to a reduced apoptosis and an excess survival. This allows propagation of cells with damaged DNA resulting in increased genetic instability and enhanced risk of cancer. The contribution of each of the p53 functions, or the lack thereof, to tumor initiation and progression has been studied in vivo, in genetically modified mice. Mice with deletions of one or both p53 alleles have been crossed with mice expressing dominant oncogenes, or lacking other tumor suppressor genes, in order to analyse the genetic interaction between different tumorigenic pathways in vivo. These studies have defined how oncogenic mutations can cooperate in tumorigenesis in tissue and the tumor-specific ways.
Export Options
About this article
Cite this article as:
Martin-Zanca Dionisio, Studies of p53 Tumor Suppression Activity in Mouse Models, Current Genomics 2002; 3 (4) . https://dx.doi.org/10.2174/1389202023350336
DOI https://dx.doi.org/10.2174/1389202023350336 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Estrogen Receptor Beta (ERβ) Expression in Different Subtypes of Malignant Pleural Mesothelioma
Current Respiratory Medicine Reviews Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry A Comprehensive Review on miR-200c, A Promising Cancer Biomarker with Therapeutic Potential
Current Drug Targets Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science Predictive Markers for Haematological Toxicity of Pemetrexed
Current Drug Targets Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design In Vitro and In Vivo Sirolimus for Modulation of Allogeneic Hematopoietic Stem Cell Transplantation
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Panobinostat: The Small Molecule Metalloenzyme Inhibitor with Marvelous Anticancer Activity
Current Topics in Medicinal Chemistry Onconase and Amphinase, the Antitumor Ribonucleases from Rana pipiens Oocytes
Current Pharmaceutical Biotechnology Arginine Deprivation, Autophagy, Apoptosis (AAA) for the Treatment of Melanoma
Current Molecular Medicine Multidrug Transporters as Drug Targets
Current Drug Targets α7 Nicotinic Acetylcholine Receptor Subunit in Angiogenesis and Epithelial to Mesenchymal Transition
Current Drug Targets Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets